Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
The ACR places a high priority on developing relevant, practical guidance for the rheumatology community. A current ACR project on musculoskeletal ultrasound (MSUS) will be discussed in the ACR Convergence 2024 session, Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis, on Saturday, Nov. 16. In the session, Veena K. Ranganath,…
In patients with psoriatic arthritis (PsA), their sex matters. In the session Sex Differences in Psoriatic Arthritis, Laura Coates, MD, PhD, of the University of Oxford, and Lihi Eder, MD, PhD, of the University of Toronto, will discuss sex-related differences in clinical features, disease course, treatment response and pain perception in patients with PsA. The…
What research on psoriatic arthritis to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts to be presented…
As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, will present a session reviewing the management of psoriatic arthritis. Dr. Orbai earned her medical degree from the Iuliu…